Neuphoria Therapeutics Inc. Stock-Based Compensation
Neuphoria Therapeutics Inc. (NEUP) reported Stock-Based Compensation of $351.60 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-18
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $76.34K, a 22.32% decline year-over-year.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $70.29K, a 257.05% increase year-over-year.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $93.70K, a 390.99% increase year-over-year.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $111.28K, a 316.21% increase year-over-year.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2026 was $351.60K, a 114.69% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $163.77K, a 79.90% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $814.81K, a 39.43% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.35M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $76.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $146.62K derived: sum of 2 quarters · filed 2026-09-18 | $240.32K derived: sum of 3 quarters · filed 2026-09-18 | $351.60K 10-K · filed 2026-09-18 |
| 2026-03-31 | $70.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $163.99K derived: sum of 2 quarters · filed 2026-05-15 | $275.26K 10-Q · filed 2026-05-15 | $373.53K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $93.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $204.98K 10-Q · filed 2026-02-17 | $303.25K derived: sum of 3 quarters · filed 2026-09-18 | $322.93K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $111.28K 10-Q · filed 2025-11-14 | $209.54K derived: sum of 2 quarters · filed 2026-09-18 | $229.23K derived: sum of 3 quarters · filed 2026-09-18 | $248.31K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $98.27K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $117.95K derived: sum of 2 quarters · filed 2026-09-18 | $137.04K derived: sum of 3 quarters · filed 2026-09-18 | $163.77K 10-K · filed 2026-09-18 |
| 2025-03-31 | $19.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $38.77K derived: sum of 2 quarters · filed 2026-05-15 | $65.50K 10-Q · filed 2026-05-15 | $173.22K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $19.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $45.82K 10-Q · filed 2026-02-17 | $153.54K derived: sum of 3 quarters · filed 2026-02-17 | $170.91K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $26.74K 10-Q · filed 2025-11-14 | $134.45K derived: sum of 2 quarters · filed 2025-11-14 | $151.83K derived: sum of 3 quarters · filed 2025-11-14 | $708.80K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $107.72K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $125.09K derived: sum of 2 quarters · filed 2025-09-29 | $682.07K derived: sum of 3 quarters · filed 2025-09-29 | $814.81K 10-K · filed 2025-09-29 |
| 2024-03-31 | $17.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | $574.35K derived: sum of 2 quarters · filed 2025-05-20 | $707.09K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $556.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | $689.72K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $132.74K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $1.35M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |